Catalyst Pharmaceutical Partners (CPRX) 5.37 $CPRX
Catalyst Pharmaceuticals announces Firdapse's rolling NDA submission for treating Lambert-Eaton Myasthenic Syndrome
M2 - Thu Jul 23, 4:41AM CDT
Biopharmaceutical company Catalyst Pharmaceuticals (NasdaqCM:CPRX) reported on Wednesday the start of a rolling submission of a New Drug Application (NDA) to the United States (US) Food and Drug Administration (FDA) for Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), a rare, debilitating disease.
CPRX: 5.37 (-0.37)
Catalyst Pharmaceuticals Initiates Rolling NDA Submission for Firdapse for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)
GlobeNewswire - Wed Jul 22, 12:24PM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the initiation of a rolling submission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for Firdapse(R) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). Firdapse(R) has received Breakthrough Therapy Designation from the FDA for the treatment of LEMS, as well as orphan drug designations for LEMS and congenital myasthenic syndromes (CMS).
CPRX: 5.37 (-0.37)
Insider Bets Paying Off At CPRX As New 52-Week High Reached
MarketNewsVideo.com - Mon Jul 13, 12:54PM CDT
In trading on Monday, shares of Catalyst Pharmaceuticals Inc touched a new 52-week high of $5.13/share. That's a 140.85% rise, or $3 per share from the 52-week low of $2.13 set back on 07/17/2014.
CPRX: 5.37 (-0.37)
Catalyst Pharmaceuticals elects Dr Gary Ingenito as CMO
M2 - Wed Jul 01, 4:04AM CDT
Biopharmaceutical company Catalyst Pharmaceuticals (NasdaqCM:CPRX) revealed on Tuesday that it has appointed Gary Ingenito, MD, PhD as its chief medical officer.
CPRX: 5.37 (-0.37)
Clinical Studies of Disease-Modifying Therapies & Drug Delivery Candidates Lead to New Drug Therapies & Patents for Treating Patients with Parkinson's Disease & Other Neurodegenerative Disorders
PR Newswire - Tue Jun 30, 9:11AM CDT
Over one million Americans suffer from the tremors, stiffness and slurred speech of Parkinson's disease and medications are usually the first-line treatment for this and other neurological conditions. Biopharmaceutical & Biotech companies continue to research through clinical studies to identify diagnostics and develop treatments designed to transform the lives of patients with severe diseases and other rare orphan conditions. Biotech companies in the news are: Amarantus BioScience Holdings, Inc. (OTC:AMBSD), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) and Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)
ACAD: 49.32 (-0.44), CPRX: 5.37 (-0.37), ACHN: 8.97 (-0.12), ADMS: 27.53 (-0.22)
Catalyst Pharmaceuticals Appoints Dr. Gary Ingenito as Chief Medical Officer
GlobeNewswire - Tue Jun 30, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment of Gary Ingenito, M.D., Ph.D, as Chief Medical Officer. Dr. Ingenito has more than 25 years of experience leading pharmaceutical development for drugs and biologics. In this new role, he will oversee all clinical development programs, medical affairs, regulatory and other related functions. Dr. Ingenito will report to Dr. Steven Miller, Catalyst's Chief Operating Officer and Chief Scientific Officer. Following Dr. Ingenito's joining Catalyst, the current Chief Medical Officer, Charles Gorodetzky, M.D., Ph.D, will continue to serve as a consultant to the company.
CPRX: 5.37 (-0.37)
Partial Seizure - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f3bjg6/partial_seizure) has announced the addition of the "Partial Seizure - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Partial Seizure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Catalyst Pharmaceutical Partners, Inc. - Eisai Co., Ltd. - Marinus Pharmaceuticals, Inc. - Novartis AG - Pfizer Inc. - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - UCB S.A. For more information visit http://www.researchandmarkets.com/research/f3...al_seizure
MRNS: 17.38 (+1.47), CPRX: 5.37 (-0.37), PFE: 34.78 (-0.10), NVS: 103.05 (+1.75)
Catalyst Pharmaceuticals Joins Russell 2000, 3000 and Global Indexes
GlobeNewswire - Mon Jun 29, 10:06AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the company has been added to the Russell 2000(R), the Russell 3000(R) and Russell Global Indexes, following Russell's annual reconstitution on June 26, according to a preliminary list of additions posted June 12, 2015 on the FTSE Russell website.
CPRX: 5.37 (-0.37)
Catalyst Pharmaceuticals Reports Tourette's Disorder Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 25, 4:00PM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) announced top-line results from a proof-of-concept study on vigabatrin) for treatment-refractory Tourette's disorder.
ABC: 110.12 (-4.83), VRX: 253.84 (+14.92), CPRX: 5.37 (-0.37), ACOR: 34.75 (-0.48)
Eli Lilly and Cree are big market movers
AP - Thu Jun 25, 3:46PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
LNN: 84.99 (+1.66), F: 14.61 (+0.19), WGO: 21.96 (-0.49), BOX: 16.38 (-0.25), MON: 104.05 (-1.30), MLHR: 28.41 (-0.36), MEI: 26.16 (-0.04), LLY: 86.76 (+0.38), MACK: 10.43 (unch), NFLX: 110.10 (-1.40), LEN: 52.46 (-0.73), PRXL: 66.05 (-0.07), IBM: 161.73 (+1.38), CPRX: 5.37 (-0.37), BAX: 37.97 (+0.26), LEN.B: 44.10 (-0.25), MSO: 6.12 (-0.07), CREE: 24.47 (-0.23)
Catalyst Pharma's CPP-109 shows promising results in Tourette's Disorder; shares up 6% premarket
Seeking Alpha - at Seeking Alpha - Wed Jun 24, 8:14AM CDT
CPRX: 5.37 (-0.37)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Jun 24, 8:13AM CDT
CPXX: 2.26 (+0.02), LEN: 52.46 (-0.73), BOX: 16.38 (-0.25), CPRX: 5.37 (-0.37), DEG: 21.83 (+0.03), ADHD: 7.49 (unch), TTHI: 2.26 (-0.04), MEET: 1.63 (-0.01), NVGN: 3.96 (-0.01), NBG: 1.04 (+0.06)
Catalyst Pharmaceuticals Announces Encouraging Top-Line Results in Proof-of-Concept Trial of Vigabatrin in Patients With Treatment-Refractory Tourette's Disorder
GlobeNewswire - Wed Jun 24, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced top-line results in an open-label, proof-of-concept trial of CPP-109 (vigabatrin) used to treat patients suffering from Tourette's Disorder (TD) that were refractory to all other previous treatments. One of four patients demonstrated a very clear, clinically significant reduction in tics, and two others showed about a 25% reduction in tics, but without subjective clinical improvement.
CPRX: 5.37 (-0.37)
4 Breakout Biotech Stocks Under $10 to Watch
at The Street - Thu Jun 18, 1:36PM CDT
These biotech stocks that trade for under $10 a share could be setting up to break out and trade higher soon.
IDRA: 3.95 (+0.20), CPRX: 5.37 (-0.37), AKAO: 7.17 (+0.13), CLDN: 1.26 (-0.01)
Global Tourette Syndrome Pipeline Review, H1 2015 - 9 Companies & 10 Drug Profiles
M2 - Mon Jun 08, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbs28p/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Edison Pharmaceuticals, Inc. - Neurocrine Biosciences, Inc. - Otsuka Holdings Co., Ltd. - Psyadon Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Synchroneuron Inc. Drug Profiles - acamprosate calcium SR - aripiprazole - AZD-5213 - CPP-115 - dutetrabenazine ER - ecopipam hydrochloride - RP-5063 - valbenazine - vatiquinone - vigabatrin For more information visit http://www.researchandmarkets.com/research/vb...e_syndrome
NBIX: 51.35 (-1.24), CPRX: 5.37 (-0.37), AZN: 66.55 (-0.67), ASPX: 100.96 (unch)
Global Anxiety Disorders Pipeline Review, H1 2015
M2 - Mon Jun 08, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6j3ln/anxiety_disorders) has announced the addition of the "Anxiety Disorders - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Adamed Sp. z o.o. - Addex Therapeutics Ltd - Avineuro Pharmaceuticals, Inc. - Azevan Pharmaceuticals, Inc. - Beech Tree Labs, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - C4X Discovery Ltd - Catalyst Pharmaceutical Partners, Inc. - Concert Pharmaceuticals, Inc. - Edgemont Pharmaceuticals, LLC - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GW Pharmaceuticals plc - H. Lundbeck A/S - Heptares Therapeutics Ltd. - HolsboerMaschmeyer NeuroChemie GmbH - Humanetics Corporation - Intra-Cellular Therapies, Inc. - Johnson & Johnson - Marinus Pharmaceuticals, Inc. - Merz Pharmaceuticals GmbH - MI.TO. Technology S.r.L. - Nanotherapeutics, Inc. - Neuralstem, Inc. - Neurocrine Biosciences, Inc. - NeuroNascent, Inc. - Newron Pharmaceuticals S.p.A. - Novartis AG - Nuvo Research Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/v6..._disorders
PFE: 34.78 (-0.10), LLY: 86.76 (+0.38), CNCE: 16.91 (-0.20), OMER: 17.63 (-0.21), JNJ: 100.20 (+0.02), NBIX: 51.35 (-1.24), CPRX: 5.37 (-0.37), MRNS: 17.38 (+1.47), ABBV: 70.52 (-0.04), ITCI: 29.63 (-1.08), CUR: 1.93 (+0.25), NVS: 103.05 (+1.75)
Dyskinesia - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2wzs3f/dyskinesia) has announced the addition of the "Dyskinesia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Adamas Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advicenne Pharma - Amarantus Bioscience Holdings, Inc. - Astraea Therapeutics, LLC - Auspex Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Pharmaceutical Partners, Inc. - Contera Pharma ApS - EpiVax, Inc. - Heptares Therapeutics Ltd. - Integrative Research Laboratories Sweden AB - Ipsen S.A. - Medicure Inc. - Medy-Tox Inc. - Merz Pharmaceuticals GmbH - Neurim Pharmaceuticals Ltd - Neurocrine Biosciences, Inc. - Neurolixis Inc. - Novartis AG - Osmotica Pharmaceutical Corp. - Otsuka Holdings Co., Ltd. - Santhera Pharmaceuticals Holding AG - SciFluor Life Sciences, LLC - Synchroneuron Inc. - Targacept, Inc. - Upsher-Smith Laboratories, Inc. For more information visit http://www.researchandmarkets.com/research/2wzs3f/dyskinesia
NBIX: 51.35 (-1.24), BMRN: 148.05 (+4.05), TRGT: 2.48 (unch), CPRX: 5.37 (-0.37), ASPX: 100.96 (unch), NVS: 103.05 (+1.75)
BUYINS.NET: SPSC, CHA, CTCT, CPRX, WPRT, CATM Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Jun 02, 7:49AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of SPS Commerce Inc (NASDAQ:SPSC), China Telecom Corp Ltd (NYSE:CHA), Constant Contact Inc (NASDAQ:CTCT), Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX), WESTPORT INNOVATIONS INC (NASDAQ:WPRT), CARDTRONICS INC. (NASDAQ:CATM) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
WPRT: 4.32 (-0.16), CHA: 57.51 (-0.98), CPRX: 5.37 (-0.37), SPSC: 72.32 (-1.81), CATM: 34.75 (-0.25), CTCT: 29.53 (-1.25)
Catalyst Pharmaceuticals Names Richard J. Daly Interim Chief Commercial Officer
GlobeNewswire - Thu May 28, 10:20AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment of Richard J. Daly to the position of interim Chief Commercial Officer. A member of Catalyst's board of directors, Daly, 54, will lead pre-commercial activities for Firdapse(R) while the company conducts a search for an executive to run commercial operations. He replaces David Muth, who has left the company to pursue other opportunities.
CPRX: 5.37 (-0.37), BMY: 68.24 (-1.13)
Catalyst Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference
GlobeNewswire - Wed May 27, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the Company will be presenting at the Jefferies 2015 Healthcare Conference, in New York. Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Tuesday, June 2 at 11:00 am ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
CPRX: 5.37 (-0.37)
Catalyst Pharmaceuticals announces Firdapse's rolling NDA submission for treating Lambert-Eaton Myasthenic Syndrome
M2 - Thu Jul 23, 4:41AM CDT
Biopharmaceutical company Catalyst Pharmaceuticals (NasdaqCM:CPRX) reported on Wednesday the start of a rolling submission of a New Drug Application (NDA) to the United States (US) Food and Drug Administration (FDA) for Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), a rare, debilitating disease.
CPRX: 5.37 (-0.37)
Catalyst Pharmaceuticals Initiates Rolling NDA Submission for Firdapse for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)
GlobeNewswire - Wed Jul 22, 12:24PM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the initiation of a rolling submission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for Firdapse(R) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). Firdapse(R) has received Breakthrough Therapy Designation from the FDA for the treatment of LEMS, as well as orphan drug designations for LEMS and congenital myasthenic syndromes (CMS).
CPRX: 5.37 (-0.37)
Insider Bets Paying Off At CPRX As New 52-Week High Reached
MarketNewsVideo.com - Mon Jul 13, 12:54PM CDT
In trading on Monday, shares of Catalyst Pharmaceuticals Inc touched a new 52-week high of $5.13/share. That's a 140.85% rise, or $3 per share from the 52-week low of $2.13 set back on 07/17/2014.
CPRX: 5.37 (-0.37)
Catalyst Pharmaceuticals elects Dr Gary Ingenito as CMO
M2 - Wed Jul 01, 4:04AM CDT
Biopharmaceutical company Catalyst Pharmaceuticals (NasdaqCM:CPRX) revealed on Tuesday that it has appointed Gary Ingenito, MD, PhD as its chief medical officer.
CPRX: 5.37 (-0.37)
Clinical Studies of Disease-Modifying Therapies & Drug Delivery Candidates Lead to New Drug Therapies & Patents for Treating Patients with Parkinson's Disease & Other Neurodegenerative Disorders
PR Newswire - Tue Jun 30, 9:11AM CDT
Over one million Americans suffer from the tremors, stiffness and slurred speech of Parkinson's disease and medications are usually the first-line treatment for this and other neurological conditions. Biopharmaceutical & Biotech companies continue to research through clinical studies to identify diagnostics and develop treatments designed to transform the lives of patients with severe diseases and other rare orphan conditions. Biotech companies in the news are: Amarantus BioScience Holdings, Inc. (OTC:AMBSD), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) and Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)
ACAD: 49.32 (-0.44), CPRX: 5.37 (-0.37), ACHN: 8.97 (-0.12), ADMS: 27.53 (-0.22)
Catalyst Pharmaceuticals Appoints Dr. Gary Ingenito as Chief Medical Officer
GlobeNewswire - Tue Jun 30, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment of Gary Ingenito, M.D., Ph.D, as Chief Medical Officer. Dr. Ingenito has more than 25 years of experience leading pharmaceutical development for drugs and biologics. In this new role, he will oversee all clinical development programs, medical affairs, regulatory and other related functions. Dr. Ingenito will report to Dr. Steven Miller, Catalyst's Chief Operating Officer and Chief Scientific Officer. Following Dr. Ingenito's joining Catalyst, the current Chief Medical Officer, Charles Gorodetzky, M.D., Ph.D, will continue to serve as a consultant to the company.
CPRX: 5.37 (-0.37)
Partial Seizure - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f3bjg6/partial_seizure) has announced the addition of the "Partial Seizure - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Partial Seizure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Catalyst Pharmaceutical Partners, Inc. - Eisai Co., Ltd. - Marinus Pharmaceuticals, Inc. - Novartis AG - Pfizer Inc. - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - UCB S.A. For more information visit http://www.researchandmarkets.com/research/f3...al_seizure
MRNS: 17.38 (+1.47), CPRX: 5.37 (-0.37), PFE: 34.78 (-0.10), NVS: 103.05 (+1.75)
Catalyst Pharmaceuticals Joins Russell 2000, 3000 and Global Indexes
GlobeNewswire - Mon Jun 29, 10:06AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the company has been added to the Russell 2000(R), the Russell 3000(R) and Russell Global Indexes, following Russell's annual reconstitution on June 26, according to a preliminary list of additions posted June 12, 2015 on the FTSE Russell website.
CPRX: 5.37 (-0.37)
Catalyst Pharmaceuticals Reports Tourette's Disorder Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 25, 4:00PM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) announced top-line results from a proof-of-concept study on vigabatrin) for treatment-refractory Tourette's disorder.
ABC: 110.12 (-4.83), VRX: 253.84 (+14.92), CPRX: 5.37 (-0.37), ACOR: 34.75 (-0.48)
Eli Lilly and Cree are big market movers
AP - Thu Jun 25, 3:46PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
LNN: 84.99 (+1.66), F: 14.61 (+0.19), WGO: 21.96 (-0.49), BOX: 16.38 (-0.25), MON: 104.05 (-1.30), MLHR: 28.41 (-0.36), MEI: 26.16 (-0.04), LLY: 86.76 (+0.38), MACK: 10.43 (unch), NFLX: 110.10 (-1.40), LEN: 52.46 (-0.73), PRXL: 66.05 (-0.07), IBM: 161.73 (+1.38), CPRX: 5.37 (-0.37), BAX: 37.97 (+0.26), LEN.B: 44.10 (-0.25), MSO: 6.12 (-0.07), CREE: 24.47 (-0.23)
Catalyst Pharma's CPP-109 shows promising results in Tourette's Disorder; shares up 6% premarket
Seeking Alpha - at Seeking Alpha - Wed Jun 24, 8:14AM CDT
CPRX: 5.37 (-0.37)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Jun 24, 8:13AM CDT
CPXX: 2.26 (+0.02), LEN: 52.46 (-0.73), BOX: 16.38 (-0.25), CPRX: 5.37 (-0.37), DEG: 21.83 (+0.03), ADHD: 7.49 (unch), TTHI: 2.26 (-0.04), MEET: 1.63 (-0.01), NVGN: 3.96 (-0.01), NBG: 1.04 (+0.06)
Catalyst Pharmaceuticals Announces Encouraging Top-Line Results in Proof-of-Concept Trial of Vigabatrin in Patients With Treatment-Refractory Tourette's Disorder
GlobeNewswire - Wed Jun 24, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced top-line results in an open-label, proof-of-concept trial of CPP-109 (vigabatrin) used to treat patients suffering from Tourette's Disorder (TD) that were refractory to all other previous treatments. One of four patients demonstrated a very clear, clinically significant reduction in tics, and two others showed about a 25% reduction in tics, but without subjective clinical improvement.
CPRX: 5.37 (-0.37)
4 Breakout Biotech Stocks Under $10 to Watch
at The Street - Thu Jun 18, 1:36PM CDT
These biotech stocks that trade for under $10 a share could be setting up to break out and trade higher soon.
IDRA: 3.95 (+0.20), CPRX: 5.37 (-0.37), AKAO: 7.17 (+0.13), CLDN: 1.26 (-0.01)
Global Tourette Syndrome Pipeline Review, H1 2015 - 9 Companies & 10 Drug Profiles
M2 - Mon Jun 08, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbs28p/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Edison Pharmaceuticals, Inc. - Neurocrine Biosciences, Inc. - Otsuka Holdings Co., Ltd. - Psyadon Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Synchroneuron Inc. Drug Profiles - acamprosate calcium SR - aripiprazole - AZD-5213 - CPP-115 - dutetrabenazine ER - ecopipam hydrochloride - RP-5063 - valbenazine - vatiquinone - vigabatrin For more information visit http://www.researchandmarkets.com/research/vb...e_syndrome
NBIX: 51.35 (-1.24), CPRX: 5.37 (-0.37), AZN: 66.55 (-0.67), ASPX: 100.96 (unch)
Global Anxiety Disorders Pipeline Review, H1 2015
M2 - Mon Jun 08, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6j3ln/anxiety_disorders) has announced the addition of the "Anxiety Disorders - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Adamed Sp. z o.o. - Addex Therapeutics Ltd - Avineuro Pharmaceuticals, Inc. - Azevan Pharmaceuticals, Inc. - Beech Tree Labs, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - C4X Discovery Ltd - Catalyst Pharmaceutical Partners, Inc. - Concert Pharmaceuticals, Inc. - Edgemont Pharmaceuticals, LLC - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GW Pharmaceuticals plc - H. Lundbeck A/S - Heptares Therapeutics Ltd. - HolsboerMaschmeyer NeuroChemie GmbH - Humanetics Corporation - Intra-Cellular Therapies, Inc. - Johnson & Johnson - Marinus Pharmaceuticals, Inc. - Merz Pharmaceuticals GmbH - MI.TO. Technology S.r.L. - Nanotherapeutics, Inc. - Neuralstem, Inc. - Neurocrine Biosciences, Inc. - NeuroNascent, Inc. - Newron Pharmaceuticals S.p.A. - Novartis AG - Nuvo Research Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/v6..._disorders
PFE: 34.78 (-0.10), LLY: 86.76 (+0.38), CNCE: 16.91 (-0.20), OMER: 17.63 (-0.21), JNJ: 100.20 (+0.02), NBIX: 51.35 (-1.24), CPRX: 5.37 (-0.37), MRNS: 17.38 (+1.47), ABBV: 70.52 (-0.04), ITCI: 29.63 (-1.08), CUR: 1.93 (+0.25), NVS: 103.05 (+1.75)
Dyskinesia - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2wzs3f/dyskinesia) has announced the addition of the "Dyskinesia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Adamas Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advicenne Pharma - Amarantus Bioscience Holdings, Inc. - Astraea Therapeutics, LLC - Auspex Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Pharmaceutical Partners, Inc. - Contera Pharma ApS - EpiVax, Inc. - Heptares Therapeutics Ltd. - Integrative Research Laboratories Sweden AB - Ipsen S.A. - Medicure Inc. - Medy-Tox Inc. - Merz Pharmaceuticals GmbH - Neurim Pharmaceuticals Ltd - Neurocrine Biosciences, Inc. - Neurolixis Inc. - Novartis AG - Osmotica Pharmaceutical Corp. - Otsuka Holdings Co., Ltd. - Santhera Pharmaceuticals Holding AG - SciFluor Life Sciences, LLC - Synchroneuron Inc. - Targacept, Inc. - Upsher-Smith Laboratories, Inc. For more information visit http://www.researchandmarkets.com/research/2wzs3f/dyskinesia
NBIX: 51.35 (-1.24), BMRN: 148.05 (+4.05), TRGT: 2.48 (unch), CPRX: 5.37 (-0.37), ASPX: 100.96 (unch), NVS: 103.05 (+1.75)
BUYINS.NET: SPSC, CHA, CTCT, CPRX, WPRT, CATM Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Jun 02, 7:49AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of SPS Commerce Inc (NASDAQ:SPSC), China Telecom Corp Ltd (NYSE:CHA), Constant Contact Inc (NASDAQ:CTCT), Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX), WESTPORT INNOVATIONS INC (NASDAQ:WPRT), CARDTRONICS INC. (NASDAQ:CATM) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
WPRT: 4.32 (-0.16), CHA: 57.51 (-0.98), CPRX: 5.37 (-0.37), SPSC: 72.32 (-1.81), CATM: 34.75 (-0.25), CTCT: 29.53 (-1.25)
Catalyst Pharmaceuticals Names Richard J. Daly Interim Chief Commercial Officer
GlobeNewswire - Thu May 28, 10:20AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment of Richard J. Daly to the position of interim Chief Commercial Officer. A member of Catalyst's board of directors, Daly, 54, will lead pre-commercial activities for Firdapse(R) while the company conducts a search for an executive to run commercial operations. He replaces David Muth, who has left the company to pursue other opportunities.
CPRX: 5.37 (-0.37), BMY: 68.24 (-1.13)
Catalyst Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference
GlobeNewswire - Wed May 27, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the Company will be presenting at the Jefferies 2015 Healthcare Conference, in New York. Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Tuesday, June 2 at 11:00 am ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
CPRX: 5.37 (-0.37)
